Nymox Corporation
Records under this name other than the patents Nymox Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,331,374 | Focal treatment of prostate cancer Lapsed on the fee record Ended May 17, 2026 · USPTO record | Lapsed on the fee record | Ended May 17, 2026 | USPTO record |
| US 8,716,247 | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells Lapsed on the fee record Ended May 6, 2026 · USPTO record | Lapsed on the fee record | Ended May 6, 2026 | USPTO record |
| US 11,298,400 | Method of Enhancing the Therapeutic Efficacy of Fexapotide Triflutate in Treating Luts Lapsed on the fee record Ended Apr 12, 2026 · Medium confidence | Lapsed on the fee record | Ended Apr 12, 2026 | Medium confidence |
| US 11,278,588 | Method of Treating Lower Urinary Tract Symptoms with Fexapotide Triflutate Lapsed on the fee record Ended Mar 22, 2026 · Medium confidence | Lapsed on the fee record | Ended Mar 22, 2026 | Medium confidence |
| US 11,231,421 | Methods of Treating Multifocal Cancer Lapsed on the fee record Ended Jan 25, 2026 · Medium confidence | Lapsed on the fee record | Ended Jan 25, 2026 | Medium confidence |
| US 10,835,538 | Method of treating benign prostatic hyperlasia with antibiotics Lapsed on the fee record Ended Nov 17, 2024 · USPTO record | Lapsed on the fee record | Ended Nov 17, 2024 | USPTO record |
| US 7,514,407 | Spheron component peptides and pharmaceutical compositions Term ended Term ended May 30, 2024 · USPTO record | Term ended | Term ended May 30, 2024 | USPTO record |
| US 7,408,021 | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells Term ended Term ended Mar 7, 2024 · USPTO record | Term ended | Term ended Mar 7, 2024 | USPTO record |
| US 9,243,035 | Peptides effective in the treatment of conditions requiring the removal or destruction of cells Lapsed on the fee record Ended Jan 26, 2024 · USPTO record | Lapsed on the fee record | Ended Jan 26, 2024 | USPTO record |
| US 10,532,081 | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH Lapsed on the fee record Ended Jan 14, 2024 · USPTO record | Lapsed on the fee record | Ended Jan 14, 2024 | USPTO record |